Literature DB >> 32239376

Exercise Attenuates Ribosomal Protein Six Phosphorylation in Fatty Liver Disease.

Jonathan G Stine1,2,3,4, Dandan Xu5, Kathryn Schmitz6,7,8,9, Christopher Sciamanna6,7,10, Scot R Kimball5.   

Abstract

INTRODUCTION: Nonalcoholic fatty liver disease (NAFLD) is the leading cause of liver disease worldwide. Nonalcoholic steatohepatitis (NASH), is a more severe type of NAFLD. Exercise improves NASH, by reversing steatosis, and may arrest fibrosis. However, the mechanisms underlying these interactions are unknown. AMP-activated protein kinase (AMPK) is a fuel-sensing enzyme that is activated by energy stress. Mammalian target of rapamycin in complex 1 (mTORC1) is a nutrient sensor that regulates protein synthesis. In NASH, AMPK activity is low and mTORC1 is high. In healthy persons, exercise activates AMPK and suppresses mTORC1. We examined the effects of exercise on hepatic ribosomal protein S6 phosphorylation, a downstream target of AMPK and mTORC1 in patients with NASH.
METHODS: Three subjects with biopsy-proven NASH underwent a structured, 20-week aerobic exercise intervention, five-days a week for 30-min at a moderate intensity (40-55% of VO2max). Immunofluorescence staining for rpS6 phosphorylation in hepatic tissue was quantified by ImageJ software.
RESULTS: Following 20-weeks of aerobic exercise, rpS6 levels were significantly attenuated (3.9 ± 1.9 pre-exercise vs. 1.4 +/0.4 post-exercise, p = 0.04).
CONCLUSIONS: These findings suggest exercise modulates the AMPK/mTORC1 pathway in patients with NASH and may guide the design of future studies into the mechanism of how exercise improves NASH and possibly reverses fibrosis.

Entities:  

Keywords:  Fatty liver; Fitness; Mechanism; Nonalcoholic fatty liver disease; Physical activity

Mesh:

Substances:

Year:  2020        PMID: 32239376      PMCID: PMC7529701          DOI: 10.1007/s10620-020-06226-1

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  26 in total

Review 1.  The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases.

Authors:  Naga Chalasani; Zobair Younossi; Joel E Lavine; Michael Charlton; Kenneth Cusi; Mary Rinella; Stephen A Harrison; Elizabeth M Brunt; Arun J Sanyal
Journal:  Hepatology       Date:  2017-09-29       Impact factor: 17.425

2.  Regular exercise decreases liver tumors development in hepatocyte-specific PTEN-deficient mice independently of steatosis.

Authors:  Anne-Christine Piguet; Uttara Saran; Cedric Simillion; Irene Keller; Luigi Terracciano; Helen L Reeves; Jean-François Dufour
Journal:  J Hepatol       Date:  2015-01-23       Impact factor: 25.083

3.  Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial.

Authors:  Zobair M Younossi; Vlad Ratziu; Rohit Loomba; Mary Rinella; Quentin M Anstee; Zachary Goodman; Pierre Bedossa; Andreas Geier; Susanne Beckebaum; Philip N Newsome; David Sheridan; Muhammad Y Sheikh; James Trotter; Whitfield Knapple; Eric Lawitz; Manal F Abdelmalek; Kris V Kowdley; Aldo J Montano-Loza; Jerome Boursier; Philippe Mathurin; Elisabetta Bugianesi; Giuseppe Mazzella; Antonio Olveira; Helena Cortez-Pinto; Isabel Graupera; David Orr; Lise Lotte Gluud; Jean-Francois Dufour; David Shapiro; Jason Campagna; Luna Zaru; Leigh MacConell; Reshma Shringarpure; Stephen Harrison; Arun J Sanyal
Journal:  Lancet       Date:  2019-12-05       Impact factor: 79.321

4.  Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis.

Authors:  Arun J Sanyal; Naga Chalasani; Kris V Kowdley; Arthur McCullough; Anna Mae Diehl; Nathan M Bass; Brent A Neuschwander-Tetri; Joel E Lavine; James Tonascia; Aynur Unalp; Mark Van Natta; Jeanne Clark; Elizabeth M Brunt; David E Kleiner; Jay H Hoofnagle; Patricia R Robuck
Journal:  N Engl J Med       Date:  2010-04-28       Impact factor: 91.245

5.  PNPLA3 gene polymorphism and response to lifestyle modification in patients with nonalcoholic fatty liver disease.

Authors:  Jiayun Shen; Grace Lai-Hung Wong; Henry Lik-Yuen Chan; Ruth Suk-Mei Chan; Hoi-Yun Chan; Winnie Chiu-Wing Chu; Bernice Ho-Ki Cheung; David Ka-Wai Yeung; Liz Sin Li; Mandy Man-Mei Sea; Jean Woo; Vincent Wai-Sun Wong
Journal:  J Gastroenterol Hepatol       Date:  2015-01       Impact factor: 4.029

Review 6.  Nonalcoholic fatty liver disease: a systematic review.

Authors:  Mary E Rinella
Journal:  JAMA       Date:  2015-06-09       Impact factor: 56.272

7.  Editorial: Age and Non-Invasive Markers of Fibrosis in Patients With Nonalcoholic Fatty Liver Disease: Time to Adjust the Clock?

Authors:  Jonathan G Stine; Mary E Rinella
Journal:  Am J Gastroenterol       Date:  2017-05       Impact factor: 10.864

8.  NASH Leading Cause of Liver Transplant in Women: Updated Analysis of Indications For Liver Transplant and Ethnic and Gender Variances.

Authors:  Mazen Noureddin; Aarshi Vipani; Catherine Bresee; Tsuyoshi Todo; Irene K Kim; Naim Alkhouri; Veronica Wendy Setiawan; Tram Tran; Walid S Ayoub; Shelly C Lu; Andrew S Klein; Vinay Sundaram; Nicholas N Nissen
Journal:  Am J Gastroenterol       Date:  2018-06-08       Impact factor: 12.045

Review 9.  mTORC1 signaling in hepatic lipid metabolism.

Authors:  Jinbo Han; Yiguo Wang
Journal:  Protein Cell       Date:  2017-04-22       Impact factor: 14.870

Review 10.  Role of gut microbiota and oxidative stress in the progression of non-alcoholic fatty liver disease to hepatocarcinoma: Current and innovative therapeutic approaches.

Authors:  Antonella Borrelli; Patrizia Bonelli; Franca Maria Tuccillo; Ira D Goldfine; Joseph L Evans; Franco Maria Buonaguro; Aldo Mancini
Journal:  Redox Biol       Date:  2018-02-03       Impact factor: 11.799

View more
  3 in total

1.  Exercise as Medicine: The Impact of Exercise Training on Nonalcoholic Fatty Liver Disease.

Authors:  Audrey Thorp; Jonathan G Stine
Journal:  Curr Hepatol Rep       Date:  2020-09-09

2.  Exercise Training Reverses Gut Dysbiosis in Patients With Biopsy-Proven Nonalcoholic Steatohepatitis: A Proof of Concept Study.

Authors:  Alexa Hughes; Jessica Dahmus; Gloriany Rivas; Breianna Hummer; Jeremy R Chen See; Justin R Wright; Regina Lamendella; Kathryn H Schmitz; Christopher Sciamanna; Mack Ruffin; Andrew D Patterson; Rohit Loomba; Jonathan G Stine
Journal:  Clin Gastroenterol Hepatol       Date:  2020-08-31       Impact factor: 13.576

Review 3.  Change in MRI-PDFF and Histologic Response in Patients With Nonalcoholic Steatohepatitis: A Systematic Review and Meta-Analysis.

Authors:  Jonathan G Stine; Nagambika Munaganuru; Abbey Barnard; Jennifer L Wang; Kellee Kaulback; Curtis K Argo; Siddarth Singh; Kathryn J Fowler; Claude B Sirlin; Rohit Loomba
Journal:  Clin Gastroenterol Hepatol       Date:  2020-08-31       Impact factor: 11.382

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.